The FDA has approved an immunotherapy combination therapy for adult patients with Bacillus Calmette-Guérin-naive, high-risk ...

Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG ...

Every year, about 85,000 Americans are diagnosed with bladder cancer. While treatment is often successful, bladder cancer has one of the highest rates of recurrence of any cancer: Following treatment, ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder cancer ...

What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG ...

Therapeutic progress has accelerated, with multiple recent approvals improving outcomes across early-stage, muscle-invasive, and metastatic urothelial carcinoma. FGFR3 and HER2 protein expression by ...